SG11201810923YA - SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE - Google Patents
SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDEInfo
- Publication number
- SG11201810923YA SG11201810923YA SG11201810923YA SG11201810923YA SG11201810923YA SG 11201810923Y A SG11201810923Y A SG 11201810923YA SG 11201810923Y A SG11201810923Y A SG 11201810923YA SG 11201810923Y A SG11201810923Y A SG 11201810923YA SG 11201810923Y A SG11201810923Y A SG 11201810923YA
- Authority
- SG
- Singapore
- Prior art keywords
- igg
- binding peptide
- site
- labeled antibody
- specific radioisotope
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016117395 | 2016-06-13 | ||
JP2016227025 | 2016-11-22 | ||
PCT/JP2017/021558 WO2017217347A1 (fr) | 2016-06-13 | 2017-06-12 | ANTICORPS MARQUÉ PAR RADIOISOTOPE SPÉCIFIQUE D'UN SITE UTILISANT UN PEPTIDE LIANT UNE IgG |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810923YA true SG11201810923YA (en) | 2019-01-30 |
Family
ID=60663283
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810923YA SG11201810923YA (en) | 2016-06-13 | 2017-06-12 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE |
SG10202012408UA SG10202012408UA (en) | 2016-06-13 | 2017-06-12 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202012408UA SG10202012408UA (en) | 2016-06-13 | 2017-06-12 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200181196A1 (fr) |
EP (1) | EP3470418A4 (fr) |
JP (2) | JP6959616B2 (fr) |
KR (2) | KR20230027320A (fr) |
CN (1) | CN109071606A (fr) |
CA (1) | CA3026520A1 (fr) |
SG (2) | SG11201810923YA (fr) |
WO (1) | WO2017217347A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201709573YA (en) * | 2015-05-20 | 2017-12-28 | Univ Kagoshima | Specific modification of antibody with igg-binding peptide |
KR20200002858A (ko) * | 2017-04-28 | 2020-01-08 | 아지노모토 가부시키가이샤 | 가용성 단백질에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염 |
WO2018230257A1 (fr) * | 2017-06-16 | 2018-12-20 | 国立大学法人鹿児島大学 | PEPTIDE DE LIAISON À L'IgG ET MODIFICATION SPÉCIFIQUE D'ANTICORPS AVEC LEDIT PEPTIDE |
TW202003556A (zh) | 2018-04-16 | 2020-01-16 | 日商日本醫事物理股份有限公司 | 改性抗體及放射性金屬標示抗體 |
EP3811978A4 (fr) * | 2018-06-14 | 2022-03-16 | Ajinomoto Co., Inc. | Substance ayant une affinité pour un anticorps, et composé ou sel de celui-ci possédant un groupe fonctionnel bioorthogonal |
WO2019240287A1 (fr) * | 2018-06-14 | 2019-12-19 | 味の素株式会社 | Composé comprenant une substance ayant une affinité pour un anticorps, site de clivage et groupe réactif, ou sel correspondant |
WO2020090979A1 (fr) * | 2018-10-31 | 2020-05-07 | 味の素株式会社 | Composé comprenant une substance ayant une affinité pour un anticorps, site de clivage et groupe réactif ou sel correspondant |
CN110007019A (zh) * | 2019-03-29 | 2019-07-12 | 绿城农科检测技术有限公司 | 一种同时定量检测母乳中三种抗体含量的方法 |
JP7356677B2 (ja) * | 2019-05-22 | 2023-10-05 | 学校法人東京薬科大学 | 複合体 |
US20230248854A1 (en) * | 2019-10-18 | 2023-08-10 | Nihon Medi-Physics Co., Ltd. | Method for producing radioactive metal-labeled antibody |
CN114585393A (zh) * | 2019-10-18 | 2022-06-03 | 日本医事物理股份有限公司 | Ri-标记的人源化抗体 |
US20230390425A1 (en) | 2020-10-16 | 2023-12-07 | Nihon Medi-Physics Co., Ltd. | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical |
KR20230092982A (ko) | 2020-10-22 | 2023-06-26 | 니혼 메디피직스 가부시키가이샤 | 방사성 지르코늄 착체의 제조 방법 |
EP4276855A1 (fr) | 2021-01-08 | 2023-11-15 | Nihon Medi-Physics Co., Ltd. | Procédé de production d'une solution de ac-225 et procédé de production d'un médicament faisant intervenir une solution de ac-225 |
WO2022196675A1 (fr) | 2021-03-16 | 2022-09-22 | 味の素株式会社 | Complexe ou son sel, et procédé de fabrication associé |
AU2022250323A1 (en) | 2021-03-31 | 2023-11-09 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
JPWO2022224980A1 (fr) | 2021-04-20 | 2022-10-27 | ||
CN117377696A (zh) | 2021-04-21 | 2024-01-09 | 日本医事物理股份有限公司 | 用放射β射线的核素标记的人源化抗体 |
WO2022225007A1 (fr) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | Agent antitumoral radioactif |
WO2023277144A1 (fr) * | 2021-06-30 | 2023-01-05 | 日本メジフィジックス株式会社 | Anticorps humanisé capable de se lier à la protéine heg1 et complexe dudit anticorps et d'une espèce nucléaire radioactive |
TW202325343A (zh) | 2021-08-31 | 2023-07-01 | 日商日本醫事物理股份有限公司 | 去醣基化抗體之放射性複合體,及放射性醫藥 |
CA3231257A1 (fr) | 2021-09-08 | 2023-03-16 | Yuji Ito | Compose, sel du compose, reactif de modification d'anticorps, procede de production d'anticorps modifie, et anticorps modifie |
WO2023171809A1 (fr) * | 2022-03-11 | 2023-09-14 | 日本メジフィジックス株式会社 | Procédé de production d'un réactif de modification de molécule contenant fc |
WO2023190402A1 (fr) * | 2022-03-30 | 2023-10-05 | 日本メジフィジックス株式会社 | Procédé de production de complexe |
CN117466980A (zh) * | 2023-11-02 | 2024-01-30 | 浙江普罗亭健康科技有限公司 | 基于多肽链骨架应用于金属抗体标记的负载金属缀合物及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
US5849261A (en) * | 1991-02-08 | 1998-12-15 | Diatide, Inc. | Radiolabeled vasoactive intestinal peptides for diagnosis and therapy |
US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US7074405B1 (en) * | 1998-06-22 | 2006-07-11 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
EP1757701A1 (fr) * | 1999-12-24 | 2007-02-28 | Genentech, Inc. | Procédés et compositions pour la prolongation de la demi-vie d'élimination des composés bioactifs |
US7230085B2 (en) * | 2001-11-28 | 2007-06-12 | Immunomedics, Inc. | Anti-DOTA antibody |
WO2003101495A1 (fr) * | 2002-05-29 | 2003-12-11 | Immunomedics, Inc. | Techniques et compositions destinees a la radio-immunotherapie des tumeurs du systeme nerveux central et du cerveau |
WO2008054030A1 (fr) * | 2006-11-02 | 2008-05-08 | Kagoshima University | Peptide liant l'igg |
CN103890174B (zh) * | 2011-08-24 | 2015-12-23 | 大塚化学株式会社 | IgG结合性肽及利用其检测和纯化IgG的方法 |
SG11201709573YA (en) * | 2015-05-20 | 2017-12-28 | Univ Kagoshima | Specific modification of antibody with igg-binding peptide |
-
2017
- 2017-06-12 SG SG11201810923YA patent/SG11201810923YA/en unknown
- 2017-06-12 JP JP2018523879A patent/JP6959616B2/ja active Active
- 2017-06-12 US US16/309,272 patent/US20200181196A1/en active Pending
- 2017-06-12 EP EP17813244.5A patent/EP3470418A4/fr active Pending
- 2017-06-12 CN CN201780025871.0A patent/CN109071606A/zh active Pending
- 2017-06-12 KR KR1020237005091A patent/KR20230027320A/ko not_active Application Discontinuation
- 2017-06-12 KR KR1020187035255A patent/KR20190018423A/ko not_active IP Right Cessation
- 2017-06-12 SG SG10202012408UA patent/SG10202012408UA/en unknown
- 2017-06-12 CA CA3026520A patent/CA3026520A1/fr active Pending
- 2017-06-12 WO PCT/JP2017/021558 patent/WO2017217347A1/fr unknown
-
2021
- 2021-09-30 JP JP2021160840A patent/JP7165366B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2022008678A (ja) | 2022-01-13 |
WO2017217347A1 (fr) | 2017-12-21 |
TW201802108A (zh) | 2018-01-16 |
EP3470418A1 (fr) | 2019-04-17 |
KR20230027320A (ko) | 2023-02-27 |
SG10202012408UA (en) | 2021-01-28 |
JP6959616B2 (ja) | 2021-11-02 |
US20200181196A1 (en) | 2020-06-11 |
CA3026520A1 (fr) | 2017-12-21 |
JPWO2017217347A1 (ja) | 2019-05-09 |
EP3470418A4 (fr) | 2019-12-11 |
KR20190018423A (ko) | 2019-02-22 |
CN109071606A (zh) | 2018-12-21 |
JP7165366B2 (ja) | 2022-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810923YA (en) | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE | |
CL2019002855A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno. | |
PH12019500270A1 (en) | Combination therapy for cancer | |
MX2018010445A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
IL265330A (en) | Anti-steap2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Compounds That Bind Steap2 and CD3, and Their Uses | |
IL263600A (en) | Antibodies against b7-h3 and conjugates of drug and antibody | |
BR112019001589A2 (pt) | anticorpos anti-tim-3 | |
MX2020001879A (es) | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
WO2017004026A8 (fr) | Anticorps anti-cd 123 et conjugués et dérivés correspondants | |
MY191146A (en) | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof | |
MY192822A (en) | An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use | |
CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
SG11202103670XA (en) | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex | |
MA38797A1 (fr) | Protéine de fusion thérapeutique | |
MX2019002968A (es) | Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal. | |
MX2017015039A (es) | Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20. | |
SG11202009990UA (en) | Modified antibody and radioactive metal-labelled antibody | |
SA518391121B1 (ar) | 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا | |
IL275765A (en) | Anti-tissue-mediated antibodies, antibody-drug conjugates, and related methods | |
IL277575A (en) | Antibodies to Celtic radionuclides | |
GB2548653A (en) | Immunoassay utilizing trapping conjugate | |
SG11202011232VA (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
IL265645A (en) | Monoclonal cmet binding agents, their drug conjugates and uses thereof | |
MX2015010145A (es) | Agente de formacion de inmunoimagenes para el uso con la terapia de conjugado de anticuerpo-farmaco. |